Article Details

Eight-year data from APHINITY study show Roche's Perjeta-based regimen continues to ...

Retrieved on: 2022-07-14 16:43:49

Tags for this article:

Click the tags to see associated articles and topics

Eight-year data from APHINITY study show Roche's Perjeta-based regimen continues to .... View article details on hiswai:

Excerpt

Basel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit ...

Article found on: www.marketscreener.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up